Rachel Weil

Icahn School of Medicine at Mount Sinai

Papers

1

Total Citations

15

H-Index

1

About

Dr. Rachel Weil is a leading urologic oncologist whose research focuses on improving the diagnostic accuracy and clinical outcomes for prostate cancer patients. Her work centers on the critical intersection of advanced imaging, biopsy techniques, and pathological grading, aiming to refine risk stratification and reduce overtreatment. Dr. Weil’s major contributions include demonstrating the superiority of multiparametric magnetic resonance imaging (mpMRI)-guided fusion biopsy over standard 12-core biopsy in reducing the downgrading of Grade Group after radical prostatectomy. Her 2019 study on this topic, which has garnered 15 citations, provided pivotal evidence that targeted fusion biopsy offers a more reliable assessment of tumor aggressiveness, thereby enhancing surgical planning and patient counseling. This work has helped establish a new standard for pre-operative evaluation, directly impacting clinical decision-making. Dr. Weil’s research is essential reading for clinicians and researchers seeking to understand how modern imaging can refine prostate cancer management and improve the precision of pathological grading.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
Downgrading of Grade Group After Radical Prostatectomy: Comparison of Multiparametric Magnetic Resonance Imaging Guided Fusion Biopsy and Standard 12-Core Biopsy
15 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Icahn School of Medicine at Mount Sinai

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago